Abstract: An implantable cranial medical device includes a first fluid flow path, a second fluid flow path, and upper flange portion, and a lower portion. The upper flange portion is configured to rest on a skull of a subject about a burr hole. The lower portion is configured to be placed within the burr hole. The first fluid flow path may extend from a first opening in the upper flange portion to a first opening in the lower portion. The second fluid flow path may extend from a second opening in the upper flange portion to a second opening in the lower portion.

Abstract: An implantable medical device for delivering therapeutic fluid to, and withdrawing cerebrospinal fluid (CSF) from, a CSF-containing space, includes a first inlet configured to be accessed by a needle of an aspiration device; a first outlet; a first fluid pathway extending from the first inlet to the first outlet; a second inlet; a second outlet; and a second fluid pathway extending from the second inlet to the second outlet. The first fluid pathway is free of a filter configured to prevent passage of a microbe.

Abstract: An implantable cranial medical device includes a first fluid flow path, a second fluid flow path, and upper flange portion, and a lower portion. The upper flange portion is configured to rest on a skull of a subject about a burr hole. The lower portion is configured to be placed within the burr hole. The first fluid flow path may extend from a first opening in the upper flange portion to a first opening in the lower portion. The second fluid flow path may extend from a second opening in the upper flange portion to a second opening in the lower portion.

Abstract: A system includes a first port comprising a first inlet, a first outlet, a first fluid pathway extending from the first inlet to the first outlet, a second inlet, a second outlet, and a second fluid pathway extending from the second inlet to the second outlet. The system further includes one or more CSF catheters having a first lumen, a first distal opening in fluid communication with the first lumen, a second lumen, and a second distal opening in fluid communication with the second lumen. The one or more CSF catheters are, or are configured to be, operatively coupled with the first implantable device such that the first lumen is in fluid communication with the first fluid pathway and the second lumen is in fluid communication with the second fluid pathway. At least the first distal opening is configured to be placed in the CSF-containing space. The system further includes a second port having a third inlet, a third outlet, and a third fluid pathway extending from the third inlet to the third outlet.

Abstract: Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment of pain by inhibiting the NF?B family of transcription factors.

Abstract: Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment of pain by inhibiting the NF?B family of transcription factors.

Abstract: Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment of pain by inhibiting the NF?B family of transcription factors.

Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include amyloid beta (A?), and the methods, agents and devices are useful for reducing the accumulation of A?, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A?, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral antibodies to A?, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include amyloid beta (A?), and the methods, agents and devices are useful for reducing the accumulation of A?, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A?, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral antibodies to A?, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Abstract: Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NF?B family of transcription factors.

Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include A?, and the methods, agents and devices are useful for reducing the accumulation of A?, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A?, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral of antibodies to A?, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Abstract: Humanized anti-A? antibodies derived from a murine antibody directed to a N-terminal epitope of A? are described. The humanized antibodies have reduced or no human T cell epitopes and bind A? with an affinity similar to that of the murine antibody.

Abstract: Humanized anti-A? antibodies derived from a murine antibody directed to a N-terminal epitope of A? are described. The humanized antibodies have reduced or no human T cell epitopes and bind A? with an affinity similar to that of the murine antibody.

Abstract: Humanized anti-A? antibodies derived from a murine antibody directed to a N-terminal epitope of A? are described. The humanized antibodies have reduced or no human T cell epitopes and bind A? with an affinity similar to that of the murine antibody.

Abstract: Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, is provided to attenuate an immune response, including an inflammatory immune response. Devices such as pulse generators and drug pumps may be used to stimulate the sympathetic nervous system to attenuate an immune response. Systems optionally having one or more sensors and operator instructions may also be used. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.

Abstract: A system includes (i) a medium having a solid support to which an antibody directed to target molecule is bound, (ii) a reservoir for containing the medium, (iii) a first catheter, and (iv) a second catheter. The first catheter has a proximal end portion, an opening for removal of cerebrospinal fluid from a subject, and a lumen extending from the proximal end portion to the opening. The first catheter is operably couplable to the reservoir such that fluid is capable of flowing from the lumen to the reservoir. The second catheter has a proximal end portion, a delivery region for returning cerebrospinal fluid to the subject, and a lumen extending from the proximal end portion to the delivery region. The second catheter is operably couplable to the reservoir such that fluid is capable of flowing from the reservoir to the lumen.

Abstract: Humanized anti-A? antibodies derived from a murine antibody directed to a N-terminal epitope of A? are described. The humanized antibodies have reduced or no human T cell epitopes and bind A? with an affinity similar to that of the murine antibody.

Abstract: Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include A?, and the methods, agents and devices are useful for reducing the accumulation of A?, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A?, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral of antibodies to A?, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Abstract: Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, to attenuate an immune response, including an inflammatory immune response, is discussed. Devices and systems to stimulate the sympathetic nervous system to attenuate an immune response are also discussed. Devices discussed include pulse generators and drug pumps. Systems are described as optionally having one or more sensors and operator instructions. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.